InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
3
Disclosed sells
1
T+90 hit rate
71%
T+90 mean return
+23.8%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Donley Matthew Maxwell, Vice-Président Exécutif. Insider active across 1 company, notably Aurinia Pharmaceuticals Inc.. Cumulatively, 8 filings have been recorded. Split: 3 buys · 1 sell. Total volume traded: €416k. Activity tracked since 11 May 2021. The latest transaction was disclosed on 28 February 2025 (Attribution). Regulator: SEC (Form 4). The full history is free.
Declarations8 total
82,781 shares0Common StockSEC:0001600620-25-000018:0
40,665 shares@ US$5.5149.6% of flowCommon StockSEC:0001600620-24-000036:0
216,666 shares0Common StockSEC:0001600620-24-000020:0
271,134 sharesCommon StockSEC:0001628280-23-006532:0
▲
10,000 shares@ US$4.6610.8% of flowCommon StockSEC:0001628280-22-030745:0
Ideal exit: 18 Aug 2023 (T+270)
8,500 shares0Common StockSEC:0001628280-22-005129:0
▲
9,900 shares@ US$10.074650.0% of flowCommon StockSEC:0001628280-21-010023
Ideal exit: 5 Feb 2022 (T+270)
▲
9,900 shares@ US$10.07460.0039% mcap50.0% of flowCommon StockSEC:0001628280-21-010023:0
Ideal exit: 5 Feb 2022 (T+270)
8 of 8 declarations
About Donley Matthew Maxwell
Matthew Maxwell Donley is the Executive Vice President of International Operations at Aurinia Pharmaceuticals Inc. In this role, he oversees international operations and contributes to the company's strategy. His experience in the pharmaceutical sector allows him to provide valuable insights on innovation and research. He is committed to supporting growth initiatives.
